COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1364-8535
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
COVID-19: opening a new paradigm in thromboprophylaxis for critically ill patients? ; volume:24 ; number:1 ; day:11 ; month:6 ; year:2020 ; pages:1-3 ; date:12.2020
Critical care ; 24, Heft 1 (11.6.2020), 1-3, 12.2020
- Urheber
-
Ferrandis, Raquel
Llau, Juan V.
Quintana, Manuel
Sierra, Pilar
Hidalgo, Francisco
Cassinello, Concepción
Gómez-Luque, Aurelio
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13054-020-03052-9
- URN
-
urn:nbn:de:101:1-2020081001155363844207
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:51 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ferrandis, Raquel
- Llau, Juan V.
- Quintana, Manuel
- Sierra, Pilar
- Hidalgo, Francisco
- Cassinello, Concepción
- Gómez-Luque, Aurelio
- SpringerLink (Online service)
Ähnliche Objekte (12)
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial
Videolaryngoscopy in critically ill patients
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial
Videolaryngoscopy in critically ill patients
Thromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
Dosing of thromboprophylaxis and mortality in critically ill COVID-19 patients
Risk factors for and prediction of mortality in critically ill medical–surgical patients receiving heparin thromboprophylaxis
High level of venous thromboembolism in critically ill trauma patients despite early and well-driven thromboprophylaxis protocol
Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors
Mortality data from omission of early thromboprophylaxis in critically ill patients highlights the importance of an individualised diagnosis-related approach
Large variation in anti-factor Xa levels with nadroparin as thromboprophylaxis in COVID-19 and non-COVID-19 critically ill patients
Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol
Thromboprophylaxis using combined intermittent pneumatic compression and pharmacologic prophylaxis versus pharmacologic prophylaxis alone in critically ill patients: study protocol for a randomized controlled trial